Details for New Drug Application (NDA): 211271
✉ Email this page to a colleague
NDA 211271 describes PYRIMETHAMINE, which is a drug marketed by Alvogen, Aurobindo Pharma Ltd, Sanaluz, and Teva Pharms, and is included in four NDAs. It is available from four suppliers. Additional details are available on the PYRIMETHAMINE profile page.
The generic ingredient in PYRIMETHAMINE is pyrimethamine. There are three drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the pyrimethamine profile page.
The generic ingredient in PYRIMETHAMINE is pyrimethamine. There are three drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the pyrimethamine profile page.
Summary for 211271
| Tradename: | PYRIMETHAMINE |
| Applicant: | Alvogen |
| Ingredient: | pyrimethamine |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 211271
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 25MG | ||||
| Approval Date: | Jul 27, 2021 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
